Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
O-desmethylamphetamine
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
O-desmethylamphetamine is a chemically non-existent compound that appears to be a hallucinated expansion of the abbreviation **O-DMA**. In biological literature, O-DMA refers to **O-desmethylangolensin**, a natural dietary soy isoflavone metabolite. O-DMA acts as a first-in-class inhibitor of the interaction between mitochondrial phosphoglycerate mutase 5 (PGAM5) and mitochondrial glutathione peroxidase 4 (mtGPX4). By preventing PGAM5-mediated dephosphorylation and subsequent degradation of mtGPX4, O-DMA suppresses mitochondrial lipid peroxidation and ferroptosis in renal tubular epithelial cells, offering therapeutic potential for the treatment of chronic kidney disease (CKD) and renal fibrosis.
02
Targets
GPX4 (Glutathione peroxidase 4)PGAM5 (Phosphoglycerate mutase 5)
Beyond the preview
Go deeper on O-desmethylamphetamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on O-desmethylamphetamine.